- Details
- Tracey Krupski explores the implementation of tele-cystoscopy to improve access to bladder cancer care in resource-challenged areas. Dr. Krupski shares research demonstrating how trained advanced practice providers can perform remote cystoscopies while urologists supervise via video connection, significantly reducing travel burden for patients in underserved regions. The study validates the approa...
|
- Details
- Sam Chang hosts Eugene Pietzak to discuss treatment options for BCG-unresponsive bladder cancer and the challenges of evaluating their comparative effectiveness. Dr. Pietzak emphasizes that while multiple FDA-approved treatments are now available, including pembrolizumab, nadofaragene, and BCG with IL-15 superagonist, comparing their efficacy is complicated by variations in trial designs, surgeon...
|
- Details
- A discussion between Zachary Klaassen and Mark Tyson explores the PIVOT-006 trial examining cretostimogene versus surveillance for intermediate-risk non-muscle invasive bladder cancer. The study evaluates this oncolytic immunotherapy in a new patient population, focusing on both low-grade and high-grade disease that meets specific AUA criteria for intermediate risk. The trial design includes an in...
|
- Details
- Zachary Klaassen and Ashish Kamat explore the evolving landscape of BCG-unresponsive bladder cancer treatment. Dr. Kamat traces the development of treatment options from the establishment of BCG-unresponsive disease criteria to the current array of approved and emerging therapies, including pembrolizumab, nadofaragene, and newer agents like TAR-200 and cretostimogene. The discussion emphasizes the...
|
- Details
- Zachary Klaassen hosts Mark Tyson to discuss the BOND-003 trial evaluating cretostimogene for BCG-unresponsive NMIBC. This study examines the mechanism by which this oncolytic immunotherapy selectively targets cancer cells by exploiting Rb pathway deficiencies and enhancing tumor-specific immunity through GM-CSF expression. The discussion highlights the treatment's promising efficacy with high com...
|
- Details
- Robert Huddart discusses the RAIDER trial examining adaptive radiotherapy for bladder cancer. The study compares standard whole-bladder treatment with two adaptive approaches: standard-dose tumor-directed therapy and dose-escalated tumor-directed therapy. The results demonstrate that adaptive radiotherapy allows safe dose escalation with low toxicity rates and well-maintained quality of life. The...
|
- Details
- Sunil Patel and Max Kates discuss a phase II trial of sequential gemcitabine and docetaxel therapy in BCG-naive non-muscle-invasive bladder cancer patients. The study demonstrates promising results with a 100% complete response rate at three months and 92% at twelve months using a combination of weekly induction therapy followed by monthly maintenance treatment. The discussion explores the logisti...
|
- Details
- Douglas Dahl discusses a Phase II trial of trimodality therapy for T1 high-grade bladder cancer, recently published in the Journal of Clinical Oncology. The study explores an alternative treatment option for patients who have failed BCG therapy and are facing radical cystectomy. The trimodality approach combines transurethral resection, chemotherapy, and radiation therapy, with results showing tha...
|
- Details
- At the 2024 LUGPA annual meeting, Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer, adjuvant pembrolizumab for high-risk renal cell carcinoma, and CA9 PET imaging for kidney cancer. He also shares survey data highlighting community urology's growin...
|
- Details
- Ashish Kamat speaks with Sunil Patel about a BCAN Think Tank breakout session focused on occupational and environmental risk factors in bladder cancer prevention. The discussion explores the impact of exposure to burn pits among military veterans and environmental hazards faced by firefighters, highlighting the complex mixture of potential carcinogens including polycyclic aromatic hydrocarbons, he...
|
